BioCryst Pharmaceuticals | Resultado Líquido





Resultado Líquido Alterar Data
Alnylam Pharmaceuticals USD 251.08M 317.36M 2025-09
BioCryst Pharmaceuticals USD -88.88M 74.85M 2024-12
Chugai Pharma JPY 128.41B 17.2B 2025-12
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
DBV Technologies USD -33.16M 8.71M 2025-09
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Gilead Sciences USD 3.05B 1.09B 2025-09
GlaxoSmithKline GBP 636M 1.38B 2025-12
Glaxosmithkline GBP 2.71B 1.27B 2025-09
Incyte USD 299.28M 124.89M 2025-12
Ionis Pharmaceuticals USD -128.61M 252.16M 2025-09
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novavax USD -121.3M 283.68M 2024-09
PTC Therapeutics USD 15.9M 80.75M 2025-09
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sarepta Therapeutics USD -179.95M 376.84M 2025-09
Ultragenyx Pharmaceutical USD -180.41M 65.46M 2025-09
Vertex Pharmaceuticals USD 1.08B 50M 2025-09


BioCryst Pharmaceuticals Resultado Líquido - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Feb 2026.